- Treatment of wild-type RAS metastatic colorectal cancer
- In patients with tumours expressing epidermal growth factor receptor
- Used as combination therapy or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated
- Used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment
- Treatment of locally advanced squamous cell cancer of the head and neck
- In combination with radiotherapy
- Treatment of recurrent/metastatic squamous cell cancer of the head and neck
- In combination with platinum-based chemotherapy
Infusion: 5mg/mL
- For dosing, local protocols used or a specialist
Monoclonal antibody anticancer
It binds to epidermal growth factor receptor, inhibiting cell growth and survival.
- Acneiform rash
- Fatigue
- Nausea
- Asthenia
- Pain
- Xeroderma
- Constipation
- Hypomagnesemia
- Dyspnea
- Pruritus
- Neuropathy
- Diarrhea
- Vomiting
- Headache
- Infection
- Stomatitis
- Nail changes
- Cough
- Insomnia
- Fever
- Infusion reaction
- Rigors
- Bone pain
- Confusion
- Arthralgia
- Anxiety
- Depression
- Dehydration
- Xerostomia
- Taste disturbance
- Hypersensitivity to components
- Breastfeeding and 2 months after discontinuing treatment
WARNING: Risk of cardiopulmonary arrest
- Cisplatin
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Erbitux | 5mg/mL | Injection | 20mL, 100mL | Merck Ltd | Merck Ltd |